Le livre de Sonia Shah a été très bien accueilli par la presse anglosaxonne, qui a souligné l'exemplarité de son travail d'enquête.

Les articles en français ne paraîtront qu'en octobre. Toutefois, vous pouvez vous reporter aux deux articles publiés par Sonia Shah, et traduits en français, dans Le Monde diplomatique de mai 2007.

Articles de Sonia Shah dans Le Monde diplomatique, mai 2007 :

Délocalisation des risques. Médicaments du Nord testés sur les pauvres du Sud.

La plaisanterie du consentement éclairé

"Shah has produced a well researched and passionately argued analysis of an important and rapidly developing field." -British Medical Journal, February 24, 2007

"A readable book that flows, at times, like a detective novel. Shah has a good story to tell. And like any competent journalist, she tells it well, with three-dimensional characters that stand out from the page, and a narrative style that carries her argument along at a brisk pace." —The Lancet, November 18, 2006

"An accessible account... important...powerful...derive[d] from a rich set of sources.... It is critical that those engaged in drug development, clinical research and its oversight, research ethics, and policy know about these stories." —New England Journal of Medicine, December 7, 2006

"Investigative journalist Sonia Shah has written a lucid, well-researched work on professional and governmental corruption and mismanagement... It deserves the attention of leaders of the medical profession and policy analysts." —JAMA: the Journal of the American Medical Association, November 1, 2006

"Her terse, unsentimental reportage is admirable, and the book offers a nuanced argument that recognises the need for testing of new drugs, but denounces the double standard between rich and poor patients." —The Guardian, October 14, 2006

"Government officials from India and other developing countries that seek to exapnd the local presence of the commercial clinical trials 'industry' should read this book, as should patient advocates everywhere." — James Love, director, Consumer Project on Technology

"Shah's The Body Hunters draws a two-pronged conclusion about Big Pharma: that it is too aggressive about 'body-hunting' vulnerable patients to test some drugs—ones that can be marketed in the West—but not aggressive enough in researching and providing others, particularly those with less profit potential." —Boston Globe, July 2, 2006. (Read the full article.)